Medicare Enrolled
Dr. Thomas Meyer, M.D.
Pulmonary Disease · Wynnewood, PA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Meyer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Meyer?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Meyer
Dr. Thomas Meyer is a pulmonary disease specialist in Wynnewood, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Meyer performed 3,190 Medicare services across 1,763 unique beneficiaries.
Between the years covered by Open Payments, Dr. Meyer received a total of $503,081 from 46 pharmaceutical and/or device companies across 734 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Meyer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in PA
$503,081 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,190
Medicare services
Top 3% in PA for pulmonary disease
1,763
Unique beneficiaries
$100
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~160 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
729 | $23 | $80 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
707 | $104 | $170 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
668 | $178 | $325 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
379 | $100 | $144 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
84 | $149 | $240 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
80 | $66 | $120 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
69 | $136 | $240 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
64 | $145 | $270 |
| Sedation by physician, initial 15 minutes Administration of a drug to induce depression of consciousness by the physician performing a procedure. This code covers the initial 15 minutes of sedation for patients aged 5 years or older. |
58 | $11 | $70 |
| Bronchoscopy with ultrasound and growth treatment A procedure using a flexible tube with a camera and ultrasound to examine the lung airways and treat any growths found. |
53 | $55 | $100 |
| New patient office visit, complex (60-74 min) | 51 | $186 | $325 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
41 | $57 | $160 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
41 | $66 | $95 |
| Lung biopsy via endoscope, 1 lobe A procedure to remove a small sample of lung tissue from one lobe using an endoscope for examination. |
38 | $143 | $650 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
35 | $16 | $20 |
| Bronchoscopy with ultrasound and lymph node sampling A procedure using an endoscope and ultrasound to examine the lung airways and collect samples from 1 to 2 lymph nodes. |
21 | $173 | $300 |
| Lung cancer screening counseling visit A visit to discuss the need for lung cancer screening using a low-dose CT scan. This service is used to determine eligibility and facilitate shared decision making. |
18 | $30 | $45 |
| Bronchial secretion aspiration via endoscope Removal of initial lung airway secretions using an endoscope. This procedure involves inserting a scope into the airways to clear fluid or mucus. |
16 | $121 | $425 |
| Bronchoscopy A diagnostic exam of the lung airways using an endoscope to visually inspect the inside of the lungs and airways. |
15 | $109 | $400 |
| Endoscopic needle biopsy of windpipe, airway, or lung A procedure where a needle is inserted through an endoscope to collect tissue samples from the windpipe, airway, or lung. |
12 | $147 | $550 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
11 | $109 | $190 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$503,081
Total received (2018-2024)
Avg $71,869/year across 7 years
Top 1% in PA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
734
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$491,320 (97.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,761 (2.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$81,771
2023
$126,212
2022
$190,697
2021
$97,442
2020
$334
2019
$3,876
2018
$2,749
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
INTUITIVE SURGICAL, INC.
$80,416
GlaxoSmithKline, LLC.
$268
AstraZeneca Pharmaceuticals LP
$261
GENZYME CORPORATION
$195
Galvanize Therapeutics, Inc
$151
Mylan Specialty L.P.
$124
Insmed, Inc.
$70
ABBVIE INC.
$45
Takeda Pharmaceuticals U.S.A., Inc.
$28
ANI Pharmaceuticals, Inc.
$27
Amgen Inc.
$27
United Therapeutics Corporation
$26
Genentech USA, Inc.
$24
Novartis Pharmaceuticals Corporation
$24
INOGEN, INC.
$24
Vifor Pharma, Inc.
$22
Merck Sharp & Dohme LLC
$21
PFIZER INC.
$20
Top 3 companies account for 99.0% of 2024 payments
All-time payments by company (2018-2024) ›
Intuitive Surgical, Inc.
$414,504
INTUITIVE SURGICAL, INC.
$80,416
AstraZeneca Pharmaceuticals LP
$1,594
GlaxoSmithKline, LLC.
$959
Boehringer Ingelheim Pharmaceuticals, Inc.
$883
Ethicon Inc.
$816
Mylan Specialty L.P.
$529
GENZYME CORPORATION
$475
Celgene Corporation
$291
Genentech USA, Inc.
$265
Galvanize Therapeutics, Inc
$253
Insmed, Inc.
$234
Philips Electronics North America Corporation
$185
Mallinckrodt Hospital Products Inc.
$133
Regeneron Healthcare Solutions, Inc.
$131
ANI Pharmaceuticals, Inc.
$127
E.R. Squibb & Sons, L.L.C.
$113
Takeda Pharmaceuticals U.S.A., Inc.
$113
Actelion Pharmaceuticals US, Inc.
$98
SANOFI-AVENTIS U.S. LLC
$96
ABBVIE INC.
$89
United Therapeutics Corporation
$78
Baxter Healthcare
$68
Novartis Pharmaceuticals Corporation
$64
Exeltis, USA Inc.
$60
Mallinckrodt Enterprises LLC
$51
Pulmonx Corporation
$49
Merck Sharp & Dohme LLC
$36
Allergan Inc.
$36
Circassia Pharmaceuticals Inc
$28
Amgen Inc.
$27
INOGEN, INC.
$24
Vifor Pharma, Inc.
$22
Mallinckrodt LLC
$22
Grifols USA, LLC
$21
Inogen, Inc.
$21
Kaleo, Inc.
$20
Auris Health, Inc.
$20
PFIZER INC.
$20
Boston Scientific Corporation
$19
Sunovion Pharmaceuticals Inc.
$18
Janssen Biotech, Inc.
$17
ERBE USA Inc
$15
Siemens Medical Solutions USA, Inc.
$14
Lilly USA, LLC
$14
Merck Sharp & Dohme Corporation
$13
Top 3 companies account for 98.7% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · AIRSUPRA · ALIYA SYSTEM · ANORO · ARALAST · AREXVY · ASMANEX · AUVI-Q · AVYCAZ · Abraxane · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · CYRAMZA · Cios Alpha · DA VINCI SP · DUAKLIR PRESSAIR · DUPIXENT · Da Vinci Surgical System · Dymista · ELIQUIS · Erleada · Esbriet · FASENRA · GLASSIA · Hillrom - Life 2000 Ventilation System · IMFINZI · INOGEN ONE G3 OXYGEN CONCENTRATOR · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · ION · MONARCH · Monarch · Monarch Platform · NUCALA · OFEV · OPDIVO · OPSUMIT · OPSUMIT MACITENTAN · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · UPTRAVI · Utibron · WINREVAIR · Wellcentive Undiv · XOLAIR · Xolair · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (98%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for pulmonary disease in PA.
Geographic Context
Pulmonary diseases within 10 mi
264
Per 100K population
30.7
County median income
$111,521
Nearest hospital
MAIN LINE HOSPITAL LANKENAU
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Meyer is a clinical cardiology specialist, with above-average Medicare volume (top 3% in PA), with speaking/promotional industry engagement in the top 1% of PA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Meyer experienced with expiratory airflow and volume test?
Based on Medicare claims data, Dr. Meyer performed 729 expiratory airflow and volume test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Meyer receive payments from pharmaceutical companies?
Yes. Dr. Meyer received a total of $503,081 from 46 companies across 734 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Meyer's costs compare to other pulmonary diseases in Wynnewood?
Dr. Meyer's average Medicare payment per service is $100. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Meyer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Wynnewood
Browse pulmonary diseases in Wynnewood ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in PA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in PA
Which PA pulmonary diseases receive the most from drug and device companies.
By company
Intuitive Surgical, Inc. Payments to Doctors
See all physicians who received payments from Intuitive Surgical, Inc.
By company
INTUITIVE SURGICAL, INC. Payments to Doctors
See all physicians who received payments from INTUITIVE SURGICAL, INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology